New Implantable Device for Sleep Apnea Set for Indian Market Launch
A groundbreaking implantable device designed to treat severe obstructive sleep apnea without the need for major airway surgery is poised to become available in India in the near future. However, medical specialists emphasize that this advanced technology will be appropriate only for a very specific and meticulously selected subset of patients.
How the Hypoglossal Nerve Stimulator Works
The technology, known as a hypoglossal nerve stimulator (HNS), functions in a manner analogous to a cardiac pacemaker. It is implanted beneath the skin in the chest area, where it continuously monitors breathing patterns during sleep. Whenever the device detects a pause in breathing, it delivers a mild stimulation to the hypoglossal nerve, which controls the movement of the tongue. This stimulation gently pushes the tongue forward, thereby preventing the collapse of the airway that typically triggers episodes of obstructive sleep apnea.
This innovative implant has the potential to help patients avoid invasive surgical procedures such as palatoplasty or excision of the tongue base, offering a less traumatic alternative for managing the condition.
Expert Insights on Technology and Patient Selection
Senior ENT surgeon Dr. Seemab Shaikh, founder national president of the Indian Association of Surgeons for Sleep Apnea (IASSA), provided detailed commentary on the device. "It is a proven technology and has been in clinical use for over two years in the United States and several other nations. We anticipate it receiving approval for use in India within this calendar year," Dr. Shaikh stated.
He further elaborated, "Patients with sleep apnea who are unable to tolerate Continuous Positive Airway Pressure (CPAP) machines or those with specific anatomical causes of airway collapse often face the prospect of undergoing invasive surgical interventions. The hypoglossal nerve stimulator implant could enable a portion of these patients to bypass such extensive procedures."
Dr. Shaikh stressed that the implant treatment will not be administered indiscriminately. "While sleep apnea is a prevalent disorder, this technology is intended for a very distinct patient profile. Only a minor subset of sleep apnea sufferers will meet the eligibility criteria. A thorough evaluation of the airway collapse pattern is essential before considering this implant. Appropriate patient selection is critical to ensuring genuine therapeutic benefit," he explained.
Prevalence and Eligibility in the Indian Context
According to data from a population study conducted by the All India Institute of Medical Sciences (AIIMS) in Bhopal, sleep apnea may affect approximately 34% of the Indian population. This statistic suggests that roughly one in every three adults in India could be experiencing some degree of the disorder. "Nevertheless, only about 5% of these patients are likely to satisfy the stringent clinical criteria necessary for receiving the implant," Dr. Shaikh noted.
Global Approval and Cost Considerations
The hypoglossal nerve stimulator technology has already secured approval from the U.S. Food and Drug Administration (USFDA). Kolkata-based ENT surgeon Dr. Deepankar Dutta, vice-president of IASSA, remarked, "More than 10,000 patients have been studied globally, and the device is currently in clinical use in the United States and several Gulf countries."
Initially, the device is projected to cost around Rs 35 lakh, rendering it inaccessible to a large number of patients in its early phases. Experts draw parallels to the trajectory of cochlear implants, which were priced at about Rs 12 lakh when first introduced in India two decades ago but now cost between Rs 5 lakh and Rs 7 lakh.
Chandigarh-based Dr. Sandeep Bansal, president of IASSA, commented, "Similar to many advanced medical technologies, costs are expected to decrease as adoption rates increase and local expertise in implantation and management develops."
The Broader Landscape of Sleep Apnea Management
Sleep apnea, characterized by repeated interruptions in breathing during sleep, is associated with serious health risks including hypertension, heart disease, diabetes, stroke, and persistent daytime fatigue. With rising obesity rates and increasingly sedentary lifestyles, specialists observe that the disorder is becoming more common across India.
While the new implant represents an additional option within the treatment spectrum, physicians underscore that accurate diagnosis, lifestyle modifications, weight management, and established therapeutic approaches will continue to form the cornerstone of comprehensive care for sleep apnea patients. It is noteworthy that March 13 is recognized globally as World Sleep Day, highlighting the importance of sleep health awareness.
